Advertisement


William G. Wierda, MD, PhD, on Lisocabtagene Maraleucel in Relapsed/Refractory CLL: TRANSCEND CLL 004

2025 ASCO Annual Meeting

Advertisement

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses two abstracts on lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). In Abstract 7037, liso-cel with ibrutinib demonstrated better efficacy and safety compared with liso-cel monotherapy, with statistically significant differences for complete response rate and overall response rate. In Abstract 7039, patients with R/R CLL/SLL who had received two or more prior lines of therapy had improved response, delayed progression, and prolonged survival with liso-cel compared with a real-world cohort treated with standard-of-care therapy. 

 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Confirmed — I have only corrected spelling errors and left all wording unchanged. Here is the revised transcript as one continuous paragraph: I'd like to summarize 2 posters that I'm presenting at ASCO this year. Poster 7039 and 7037—7039 is a poster that presents an updated analysis of liso-cel monotherapy and its analysis of a comparison of a standard of care cohort of patients that was collected through multiple databases. Those were all previously treated patients and the concept is to compare outcomes for liso-cel and patients with similar characteristics as those treated on the TRANSCEND 004 trial who received standard of care treatment and their outcomes versus the outcomes for patients treated with liso-cel monotherapy on the TRANSCEND CLL 004 trial. That analysis showed improved outcomes for patients who were treated with liso-cel. These were all previously treated patients, all had had prior exposure to a BTK inhibitor and the BCL2 inhibitor-based therapy. And the progression-free survival was significantly better at a median of 14 months with liso-cel compared to about four months with a standard of care option. And the overall survival was improved with a median overall survival for liso-cel of 33 months and the median overall survival for standard of care of about 14 months. And so this analysis and comparison in the absence of a randomized trial gives us some insight into the improved outcome seen with liso-cel monotherapy compared to a standard of care option. The other abstract is 7037. This was an analysis with a propensity score comparing outcomes for patients treated with liso-cel monotherapy, the CD19 CAR T-cell therapy, versus liso-cel with ibrutinib. Now there is data, historic data, that demonstrated an improved product could be generated if the T cells were harvested for production while patients were on ibrutinib. In addition, for patients treated with liso-cel or with a CD19 CAR T-cell therapy while on ibrutinib, there was an indication of improved progression-free survival and overall outcomes and a reduction potentially of side effects and toxicities. So this analysis was a comparison because the TRANSCEND CLL 004 trial has two cohorts—actually it had three cohorts—but two major cohorts, liso-cel monotherapy and liso-cel plus ibrutinib. And this was an analysis. And overall, the conclusion was that there were improved responses, both complete response rate and overall response rate, for patients who received the combination of liso-cel plus ibrutinib versus patients who received liso-cel monotherapy. Progression-free survival, duration of response, overall survival were similar; side effect and toxicity profile were similar. But clearly there was, based on this propensity score analysis, an improved response rate associated with combination therapy versus liso-cel monotherapy.

Related Videos

Shahzad Raza, MD, on Relapsed or Refractory AL Amyloidosis: First U.S. Trial of CAR T-Cell Therapy

Shahzad Raza, MD, of the Cleveland Clinic, reviews safety and efficacy data from Nexicart-2, the first U.S.-based trial of chimeric antigen receptor (CAR) T-cell therapy—an agent known as Nxc-201—in patients with relapsed or refractory light chain (AL) amyloidosis (Abstract 7508). 

Lung Cancer

Rami Manochakian, MD, FASCO, on Tarlatamab vs Chemotherapy for Second-Line Treatment of SCLC: Expert Point of View

Rami Manochakian, MD, FASCO, of Mayo Clinic Florida, offers his thoughts on findings from the primary analysis of the phase III DeLLphi-304 trial, which compared tarlatamab-dlle, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, with chemotherapy as a second-line treatment of patients with small cell lung cancer (SCLC) (LBA8008). 

Lung Cancer

Raffaele Califano, MD, on EGFR-Mutant Advanced NSCLC: MARIPOSA-2

Raffaele Califano, MD, of the Christie NHS Foundation Trust and the University of Manchester, discusses outcomes by osimertinib resistance mechanisms in MARIPOSA-2, a study that evaluated the efficacy of the bispecific antibody amivantamab-vmjw plus chemotherapy vs chemotherapy in patients with EGFR-mutant advanced NSCLC after disease progression on osimertinib (Abstract 8639). 

Colorectal Cancer

Heinz-Josef Lenz, MD, on MSI-H/dMMR Metastatic Colorectal Cancer: Expanded Analyses From CheckMate 8HW

Heinz-Josef Lenz, MD, of the University of Southern California Norris Comprehensive Cancer Center, reviews analyses from the CheckMate 8HW trial, which evaluated nivolumab plus ipilimumab vs chemotherapy or nivolumab monotherapy for microsatellite instability–high/mismatch repair–deficient (MSI-H/dMMR) metastatic colorectal cancer (Abstract 3501). 

Breast Cancer
Issues in Oncology

Neil M. Iyengar, MD, on Cancer Risk Reduction: Effects of Menopausal HRT and GLP-1 RAs

Neil M. Iyengar, MD, of Memorial Sloan Kettering Cancer Center, reviews several studies that aimed to answer two questions: does menopausal hormone therapy (HRT) impact overall survival and breast cancer–specific mortality in younger women diagnosed with high-risk disease (Abstract 10506); and do GLP-1 receptor agonists (GLP-1 RAs), a class of weight-loss medications, have cancer risk reduction properties (Abstracts 10507 and 10508). 

Advertisement

Advertisement




Advertisement